People look for alternative treatments for peripheral neuropathy for a reasonable reason: the standard drugs treat the pain and not the nerve, and their average effect is modest. That is a real gap, and it is worth filling. It is also the gap that the supplement industry has filled with a great deal of confident marketing and very little published data.
What follows is a grading of the non-drug options by the evidence that actually exists — what has randomized trial support, what has weak support, what has failed when properly tested, and the one intervention that outperforms every bottle on the shelf.
Start with what the label “alternative” is hiding
Most people searching for alternative medicine for neuropathy have already been told there is nothing to be done about the cause. In a large share of cases that is not true — the cause simply was not looked for thoroughly enough.
Among 107 patients whose neuropathy had been called idiopathic, 34% had impaired glucose tolerance, close to three times the rate in matched controls, and in many of them fasting glucose and HbA1c were normal. Only a two-hour oral glucose tolerance test found it.1 In a separate series of 219 idiopathic neuropathy patients, even those with entirely normal blood sugar carried a heavy burden of metabolic syndrome features, with lipid abnormalities particularly prevalent.2
So before spending money on supplements, it is worth confirming that the workup included an OGTT, a full lipid panel, B12 with methylmalonic acid, thyroid studies, and a review of medications. The 11 hidden drivers of peripheral neuropathy covers the rest of that list, and if your nerve conduction study came back normal while your feet still burn, read small fiber peripheral neuropathy symptoms and testing before concluding that nothing was found.
The strongest non-drug intervention is not a supplement
Diet and exercise directed at the metabolic terrain has better evidence than anything sold as a nerve supplement — and it is measured at the nerve, not on a questionnaire.
Thirty-two patients with impaired glucose tolerance and neuropathy received individualized diet and exercise counseling for one year, with skin biopsies at baseline and at 12 months. Intraepidermal nerve fiber density improved by 1.4 fibers per millimeter at the proximal site, and that improvement correlated with reduced neuropathic pain.3 A separate 10-week supervised aerobic and resistance program in patients with diagnosed diabetic peripheral neuropathy produced significant reductions in pain and neuropathic symptoms alongside increased intraepidermal nerve fiber branching on biopsy.4
A 2022 systematic review with meta-analysis of 41 randomized controlled trials concluded that for diabetic peripheral neuropathy the evidence now supports a specific recommendation: a combination of endurance and sensorimotor training, with benefits across balance measures, functional mobility, peroneal and sural nerve conduction velocity, and HbA1c.5
Nothing in the supplement aisle has that level of support. The practical program is in exercises for peripheral neuropathy in the feet.
Alpha-lipoic acid: real evidence, with an important qualifier
Alpha-lipoic acid is an antioxidant and the best-studied supplement in this field. A meta-analysis of four randomized, double-blind, placebo-controlled trials — ALADIN I, ALADIN III, SYDNEY and NATHAN II, totaling 1,258 patients — found a 24.1% relative improvement in the Total Symptom Score in the feet versus placebo after three weeks, with responder rates of 52.7% on alpha-lipoic acid against 36.9% on placebo. Pain, burning and numbness all improved, as did pinprick and touch-pressure sensation and ankle reflexes, with no difference in adverse event rates.6
The qualifier matters: that evidence is for 600 mg given intravenously, daily for three weeks. The oral capsules sold over the counter are not the same intervention, and their evidence is considerably weaker. If a supplement is recommended to you on the strength of “the ALADIN trials,” it is fair to ask whether the study used the oral form.
Acetyl-L-carnitine: modest, in a specific population
Acetyl-L-carnitine improved pain, vibratory perception and measures of nerve regeneration in patients with chronic diabetic neuropathy in randomized trial data, with the clearest effect in those treated earlier in the disease course.7 It is a reasonable adjunct with a real, if modest, evidence base. It is not a substitute for treating the driver.
Palmitoylethanolamide: promising, and worth reading carefully
Palmitoylethanolamide, or PEA, is a naturally occurring fatty acid amide. A systematic review and meta-analysis of 11 double-blind randomized controlled trials covering 774 patients with chronic pain found reduced pain scores relative to comparators, with no major side effects attributed to PEA in any study.8 The authors noted that optimal dosing and administration still need to be determined, and the trials pooled were across chronic pain generally rather than neuropathy alone.
PEA is one of the supportive agents we use at our St. Louis clinic, within a plan rather than as a standalone answer.
Acupuncture: low-certainty evidence, genuine effect size
A 2025 systematic review and meta-analysis of 14 randomized trials covering 1,169 participants found that, compared with sham, acupuncture may reduce pain in diabetic peripheral neuropathy by 1.44 cm on a 10 cm visual analog scale, and may reduce overall neurologic symptom severity, with little to no difference in adverse events. The authors graded the certainty of that evidence as low.9
Low certainty does not mean it does not work. It means the trials were small or at risk of bias and the estimate could move. Given the safety profile, acupuncture is a defensible thing to try alongside cause-directed treatment.
Topical capsaicin: the one that may do more than mask
High-concentration capsaicin at 8% is a prescription patch rather than a store-bought cream, but people often find it while searching for natural options because capsaicin comes from chili peppers. It works by defunctionalizing overactive nociceptive fibers in the skin, and there is published evidence of subsequent nerve fiber regeneration accompanying the pain relief.10 We use it, and it is covered in the high-concentration capsaicin protocol.
Light-based therapies: mechanistic rationale, thin trial evidence
Photobiomodulation targets cytochrome c oxidase in mitochondria and is intended to support energy production and circulation in injured nerve tissue. We offer class 4 photobiomodulation, class 3B cold laser and whole-body infrared at the clinic, and describe them on the services page.
The honest statement of the evidence is that the mechanistic rationale is coherent and the randomized trial base for diabetic peripheral neuropathy is still limited — several systematic reviews have been registered and published as protocols rather than completed syntheses. We use these therapies as adjuncts within a plan built on identifying and treating the cause, and we do not present them as the treatment.
What has failed when properly tested
This section matters as much as the others. Benfotiamine, a fat-soluble thiamine derivative sold widely for neuropathy, was tested in a 12-month randomized, placebo-controlled, double-blind trial in type 2 diabetes patients with symptomatic polyneuropathy. It raised blood levels of all six thiamine analytes measured, confirming it was absorbed and doing something biochemically. It produced no significant effect on corneal nerve fiber length, on the secondary morphometric, functional and clinical neuropathy outcomes, or on quality of life.11
That is what a well-conducted negative trial looks like, and it is a useful benchmark. Ask of any product marketed for neuropathy: has it been tested this way, and what happened?
Things worth being skeptical about
- Any product or program promising to cure, reverse or eliminate neuropathy. Nerve recovery is partial, slow and dependent on the cause. A cure claim is a marketing claim.
- Proprietary “nerve support” blends that combine a dozen ingredients at doses below those used in any trial, so no individual component reaches a studied dose.
- Fixed packages of sessions sold before a diagnosis. The number of treatments should follow clinical need and response, not a package purchased in advance.
- High-dose vitamin B6. Excess B6 causes a sensory neuropathy in its own right. More is not better here.
- Anything that requires stopping your prescribed medication to work.
How we think about this
Alternative and complementary approaches are not a separate category of medicine to us. They are treatments with an evidence base to be graded like any other. Where the evidence supports something, we use it; where it does not, we say so; and none of it substitutes for identifying what is damaging the nerve. That sequencing is set out in the Regenerve Protocol, and the full treatment landscape is in peripheral neuropathy treatments for the feet.
Talk to your physician before starting any supplement, particularly if you take anticoagulants, thyroid medication or diabetes medication, and note that alpha-lipoic acid can lower blood glucose.
Being evaluated in St. Louis
Regenerve is at 4477 Woodson Rd #104, St. Louis, MO 63134, minutes from St. Louis Lambert International Airport, and is led by Dr. Gurpreet Singh Padda, MD, MBA, MHP. The practice serves the St. Louis region, Missouri and Illinois. Electrodiagnostic testing is performed on site.
Call or text (314) 886-5902, or email info@regenerve.com. Office hours are Monday through Thursday 9:00 to 16:00 and Friday 9:00 to 13:30. Details are on the contact page and the locations page.
Before buying anything, the Nerve Damage Score is a five-question assessment that produces a large-print report you can bring to any physician.
Frequently asked questions
What is the best alternative treatment for peripheral neuropathy?
Diet and exercise aimed at the metabolic terrain has the strongest evidence, including measured regrowth of nerve fibers on skin biopsy. No supplement matches it. See exercises for peripheral neuropathy in the feet.
Does alpha-lipoic acid work for neuropathy?
The strong trial evidence is for 600 mg given intravenously over three weeks, which produced a 24.1% relative improvement in symptom scores versus placebo. Evidence for over-the-counter oral capsules is considerably weaker. See how sugar damages nerves.
Does acupuncture help neuropathy in the feet?
A meta-analysis of 14 randomized trials found acupuncture may reduce pain and neurologic symptom severity compared with sham, with low certainty of evidence and few adverse events. See peripheral neuropathy treatments for the feet.
Should I take benfotiamine for neuropathy?
A 12-month randomized placebo-controlled trial found benfotiamine raised thiamine levels but had no significant effect on nerve structure, nerve function, clinical neuropathy measures or quality of life. See functional B12 deficiency and neuropathy.
Are supplements enough on their own?
No. Supplements address one input at a time, while neuropathy is driven by the whole metabolic environment plus any nutritional, autoimmune, toxic or structural driver present. See the hidden drivers of peripheral neuropathy.
Can vitamins make neuropathy worse?
Yes. High-dose vitamin B6 can cause a sensory neuropathy of its own, so supplementing without knowing your levels can add a driver rather than remove one. See functional B12 deficiency and neuropathy.
Sources
- Singleton JR, Smith AG, Bromberg MB. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care. 2001. PMID 11473085
- Smith AG, Rose K, Singleton JR. Idiopathic neuropathy patients are at high risk for metabolic syndrome. Journal of the Neurological Sciences. 2008. PMID 18606421
- Smith AG, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006. PMID 16732011
- Kluding PM, et al. The effect of exercise on neuropathic symptoms, nerve function, and cutaneous innervation in people with diabetic peripheral neuropathy. Journal of Diabetes and its Complications. 2012. PMID 22717465
- Streckmann F, et al. Exercise and Neuropathy: Systematic Review with Meta-Analysis. Sports Medicine. 2022. PMID 34964950
- Ziegler D, Nowak H, Kempler P, Vargha P, Low PA. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabetic Medicine. 2004. PMID 14984445
- Sima AAF, et al. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Diabetes Care. 2005. PMID 15616239
- Lang-Illievich K, et al. Palmitoylethanolamide in the Treatment of Chronic Pain: A Systematic Review and Meta-Analysis of Double-Blind Randomized Controlled Trials. Nutrients. 2023. PMID 36986081
- Lan L, et al. Acupuncture for the Management of Chronic Diabetic Peripheral Neuropathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Pain and Headache Reports. 2025. PMID 40220243
- Anand P, et al. Reversing painful and non-painful diabetic neuropathy with the capsaicin 8% patch: clinical evidence for pain relief and restoration of function via nerve fiber regeneration. Frontiers in Neurology. 2022. PMID 36388188
- Ziegler D, et al. Effects of benfotiamine treatment over 12 months on morphometric, neurophysiological and clinical measures in type 2 diabetes patients with symptomatic polyneuropathy (BOND study). BMJ Open Diabetes Research & Care. 2026. PMID 41571333